MA29816B1 - Composes de benzimidazole thiophene - Google Patents

Composes de benzimidazole thiophene

Info

Publication number
MA29816B1
MA29816B1 MA30794A MA30794A MA29816B1 MA 29816 B1 MA29816 B1 MA 29816B1 MA 30794 A MA30794 A MA 30794A MA 30794 A MA30794 A MA 30794A MA 29816 B1 MA29816 B1 MA 29816B1
Authority
MA
Morocco
Prior art keywords
thiophene compounds
compounds
benzimidazole thiophene
benzimidazole
preparing
Prior art date
Application number
MA30794A
Other languages
English (en)
Inventor
Mui Cheung
Kyle Allen Emmitte
James Michael Salovich
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA29816B1 publication Critical patent/MA29816B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE BENZIMIDAZOLE THIOPHÈNE, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITS COMPOSÉS, DES PROCÉDÉS PERMETTANT DE PRÉPARER LESDITS COMPOSÉS ET L'UTILISATION LESDITS COMPOSÉS EN TANT QU'AGENTS PHARMACEUTIQUES.
MA30794A 2005-09-06 2008-03-31 Composes de benzimidazole thiophene MA29816B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71433705P 2005-09-06 2005-09-06
US78624406P 2006-03-27 2006-03-27

Publications (1)

Publication Number Publication Date
MA29816B1 true MA29816B1 (fr) 2008-09-01

Family

ID=37631488

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30794A MA29816B1 (fr) 2005-09-06 2008-03-31 Composes de benzimidazole thiophene

Country Status (29)

Country Link
US (2) US7786127B2 (fr)
EP (1) EP1937671B1 (fr)
JP (1) JP5002597B2 (fr)
KR (1) KR20080047585A (fr)
AR (1) AR055616A1 (fr)
AT (1) ATE452132T1 (fr)
AU (1) AU2006287766B2 (fr)
BR (1) BRPI0615668A2 (fr)
CA (1) CA2621879A1 (fr)
CR (1) CR9786A (fr)
CY (1) CY1109916T1 (fr)
DE (1) DE602006011192D1 (fr)
DK (1) DK1937671T3 (fr)
EA (1) EA014111B1 (fr)
ES (1) ES2337929T3 (fr)
HK (1) HK1117504A1 (fr)
HR (1) HRP20100122T1 (fr)
IL (1) IL189897A0 (fr)
JO (1) JO2578B1 (fr)
MA (1) MA29816B1 (fr)
MX (1) MX2008003173A (fr)
NO (1) NO20081160L (fr)
NZ (1) NZ566345A (fr)
PE (1) PE20070518A1 (fr)
PL (1) PL1937671T3 (fr)
PT (1) PT1937671E (fr)
SI (1) SI1937671T1 (fr)
TW (1) TW200800967A (fr)
WO (1) WO2007030361A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851495B2 (en) * 2006-05-23 2010-12-14 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP2032564A2 (fr) * 2006-06-02 2009-03-11 SmithKline Beecham Corporation Composés d'éther benzylique de benzimidazole thiophène substitué non cyclique
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
EP2032563B1 (fr) * 2006-06-02 2010-06-02 GlaxoSmithKline LLC Composés de benzimidazole thiophène
WO2008087736A1 (fr) * 2007-01-19 2008-07-24 Ube Industries, Ltd. Procédé de production d'amine aromatique ayant un groupe aralkyloxy ou hétéroaralkyloxy
EP2170871A2 (fr) * 2007-06-26 2010-04-07 GlaxoSmithKline LLC Procédés de préparation de thiophènes de benzimidazole
WO2009003911A1 (fr) * 2007-06-29 2009-01-08 4Sc Ag Thiophène-imidazopyridines
EP2100894A1 (fr) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
WO2009151914A1 (fr) * 2008-05-27 2009-12-17 Smithkline Beecham Corporation Procédés de traitement de néoplasmes au moyen d'une combinaison d'un inhibiteur de plk et d'un rétinoïde
WO2009154645A1 (fr) * 2008-06-20 2009-12-23 Smithkline Beecham Corporation Méthodes permettant de traiter des tumeurs du système nerveux central
CA2745596A1 (fr) * 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
WO2011049625A1 (fr) 2009-10-20 2011-04-28 Mansour Samadpour Procédé de criblage d'aflatoxine dans des produits
CA3022722A1 (fr) 2009-11-05 2011-05-12 Rhizen Pharmaceuticals S.A. Modulateurs de proteine kinase pi3k
EA024842B9 (ru) 2011-05-04 2017-08-31 Ризен Фармасьютикалз Са Соединения в качестве модуляторов протеинкиназы pi3k
DK3260455T3 (da) 2012-07-04 2019-06-11 Rhizen Pharmaceuticals S A Selektive pi3k delta-hæmmere
KR102574152B1 (ko) * 2020-03-27 2023-09-05 (주) 업테라 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
US20060074119A1 (en) 2002-08-08 2006-04-06 Andrews Clarence W Iii Thiophene compounds
AU2003903440A0 (en) * 2003-07-04 2003-07-17 James Hardie International Finance B.V. Rainscreen apparatus and method
JP2007509070A (ja) * 2003-10-16 2007-04-12 スミスクライン ビーチャム コーポレーション チオフェン化合物
WO2005037627A1 (fr) 2003-10-20 2005-04-28 Nsk Ltd. Dispositif de commande
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
CN101331126A (zh) * 2005-09-06 2008-12-24 史密丝克莱恩比彻姆公司 作为plk调节剂的苯并咪唑噻吩化合物
EP1924572B1 (fr) * 2005-09-06 2009-12-30 SmithKline Beecham Corporation Procede regioselectif de preparation de benzimidazole thiophenes
WO2007087283A2 (fr) 2006-01-23 2007-08-02 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides utiles en tant qu'inhibiteurs de proteines kinases
EP2032563B1 (fr) * 2006-06-02 2010-06-02 GlaxoSmithKline LLC Composés de benzimidazole thiophène
EP2032564A2 (fr) * 2006-06-02 2009-03-11 SmithKline Beecham Corporation Composés d'éther benzylique de benzimidazole thiophène substitué non cyclique

Also Published As

Publication number Publication date
AU2006287766A1 (en) 2007-03-15
HK1117504A1 (en) 2009-01-16
AR055616A1 (es) 2007-08-29
NZ566345A (en) 2010-04-30
BRPI0615668A2 (pt) 2011-05-24
JP5002597B2 (ja) 2012-08-15
HRP20100122T1 (hr) 2010-05-31
DE602006011192D1 (de) 2010-01-28
TW200800967A (en) 2008-01-01
PT1937671E (pt) 2010-03-12
PE20070518A1 (es) 2007-06-12
JP2009508816A (ja) 2009-03-05
CA2621879A1 (fr) 2007-03-15
US7786127B2 (en) 2010-08-31
CY1109916T1 (el) 2014-09-10
SI1937671T1 (sl) 2010-04-30
EA014111B1 (ru) 2010-10-29
DK1937671T3 (da) 2010-04-26
EP1937671A2 (fr) 2008-07-02
NO20081160L (no) 2008-05-29
WO2007030361A2 (fr) 2007-03-15
AU2006287766B2 (en) 2010-06-24
US20070270437A1 (en) 2007-11-22
ES2337929T3 (es) 2010-04-30
ATE452132T1 (de) 2010-01-15
US20080214567A1 (en) 2008-09-04
PL1937671T3 (pl) 2010-05-31
US7595330B2 (en) 2009-09-29
EP1937671B1 (fr) 2009-12-16
WO2007030361A3 (fr) 2007-05-31
KR20080047585A (ko) 2008-05-29
MX2008003173A (es) 2008-03-18
CR9786A (es) 2008-05-22
EA200800546A1 (ru) 2008-08-29
IL189897A0 (en) 2008-08-07
JO2578B1 (en) 2011-02-27

Similar Documents

Publication Publication Date Title
MA29816B1 (fr) Composes de benzimidazole thiophene
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
MX2010012074A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida.
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
MA30765B1 (fr) Derives innovants du thiophene
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA30042B1 (fr) Composes calcilytiques
ATE517883T1 (de) Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
MA31907B1 (fr) Nouveaux herbicides
ATE536355T1 (de) 3,3-spiroindolinionderivate als antikrebsmittel
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MXPA05007328A (es) Composiciones que contienen agentes antiacne y el uso de las mismas.
MA31898B1 (fr) Compositions pharmaceutiques
WO2007016352A3 (fr) Compositions orales liquides de losartan
TW200621160A (en) Anti-termite agent
FR2894143B1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION
BRPI0608287A2 (pt) agente endoparasiticida
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments